AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
AbCellera Biologics Inc. (ABCL) reported a Q3 loss of $0.17 per share, missing the Zacks Consensus Estimate of a $0.14 loss. This is a larger loss compared to $0.10 per share a year ago.
November 05, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AbCellera Biologics Inc. reported a larger-than-expected Q3 loss of $0.17 per share, missing the consensus estimate of $0.14 and increasing from last year's $0.10 loss.
The reported loss per share of $0.17 is worse than the expected $0.14, indicating underperformance. This, combined with a year-over-year increase in losses, suggests potential negative sentiment and short-term stock price pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100